PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30392788-0 2019 Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. regorafenib 0-11 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 24-28 30392788-2 2019 In this study, we evaluated the effect of regorafenib, an oral multi-kinase inhibitor, in inhibiting BCRP-mediated MDR in silico, in vitro and in vivo. regorafenib 42-53 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 101-105 30392788-3 2019 We found that regorafenib significantly sensitized MDR colon cancer cells to BCRP substrates by increasing their intracellular accumulation. regorafenib 14-25 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-81 30392788-5 2019 Investigation of the mechanism revealed that regorafenib stimulated BCRP ATPase activity. regorafenib 45-56 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-72 30392788-6 2019 Our induced-fit docking and molecular dynamics simulations suggested the existence of a strong and stable interaction between regorafenib and the transmembrane domain of human crystalized BCRP. regorafenib 126-137 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 188-192 30368586-4 2019 In addition, we determined the association of regorafenib concentrations with ABCG2 and OATP1B1 polymorphisms, which are regorafenib transporters. regorafenib 46-57 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 78-83 28157071-0 2017 Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study : . regorafenib 82-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 20-25 25563977-5 2015 RESULTS: Regorafenib was transported well by mAbcg2 and hABCG2 and modestly by hABCB1 in vitro. regorafenib 9-20 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 56-62